Sun.Jun 04, 2023

article thumbnail

ASCO: AstraZeneca, Daiichi's Enhertu delivers 'very compelling' pan-tumor activity, experts say

Fierce Pharma

AstraZeneca and Daiichi Sankyo’s Enhertu has already made waves in breast cancer treatment. | AstraZeneca and Daiichi Sankyo’s Enhertu has already made waves in breast cancer treatment. Now, the companies are positioning the HER2 antibody-drug conjugate for expansion into other tumor types with data that researchers view as very compelling.

133
133
article thumbnail

STAT+: Immunogen drug prolongs survival of women with advanced ovarian cancer

STAT

CHICAGO — An antibody that delivers chemotherapy directly to tumor cells extended the lives of women with a form of advanced ovarian cancer in a large study, researchers reported Sunday. The drug, called Elahere, is made by the biotech company Immunogen. It was granted conditional approval in the U.S. last November based on preliminary evidence showing it shrank tumors.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

New FGFR Inhibition Therapies Show Promise in Intrahepatic Cholangiocarcinoma

Pharmacy Times

Biliary tract cancers have become the model for precision oncology because of its complex molecular landscape.

123
123
article thumbnail

STAT+: Targeted drug greatly slows progression of a brain cancer

STAT

CHICAGO – An experimental drug dramatically slowed the growth of glioma, a type of brain cancer, if the tumor carried a specific type of genetic alteration, researchers said Sunday, potentially sparing patients exposure to radiation and chemotherapy. The drug, vorasidenib, is made by Servier Pharmaceuticals, a privately held drugmaker based in France.

article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Brexpiprazole For Alzheimer’s Agitation – Is The Juice Worth The Squeeze?

Med Ed 101

Earlier this month the FDA approved Rexulti (Brexpiprazole) for the treatment of agitation in patients with dementia due to Alzheimer’s. Originally approved as an atypical antipsychotic used for schizophrenia, or an adjunct therapy for major depressive disorder, Rexulti finds itself alone as the only medication for this indication. In the clinical trials, the Cohen-Mansfield Agitation […] The post Brexpiprazole For Alzheimer’s Agitation – Is The Juice Worth The Squeeze?

FDA 98
article thumbnail

Leading innovators with viral vectors for the pharmaceutical industry

Pharmaceutical Technology

The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Viral vectors.

More Trending

article thumbnail

ASCO 2023: Keytruda becomes a new option in perioperative NSCLC  

Pharmaceutical Technology

Early-stage non-small cell lung cancer (NSCLC) is typically treated with surgery followed by adjuvant therapy (chemo ± radiation) in patients deemed to be at higher risk. The use of a pre-surgical course of drug treatment (neoadjuvant), is not well established thus far and can differ substantially between countries and even hospitals within the same country.

article thumbnail

STAT+: ‘Extraordinary’ survival data for lung cancer patients is seen as boost for AstraZeneca drug

STAT

CHICAGO – Giving the AstraZeneca drug Tagrisso to patients with non-small cell lung cancer who have had their tumors removed reduced the risk of death by 51%, researchers said Sunday. Put another way, that would mean that about one in 10 patients who received the drug would live another five years. “I expected we’d see something, but I was getting a little anxious,” said Roy Herbst, the deputy director of the Yale Cancer Center and the lead author of the study.

83
article thumbnail

Addition of Pembrolizumab to Chemotherapy Can Significantly Improve Survival Outcomes in Patients with Cervical Cancer

Pharmacy Times

Expert discusses the long wait for an effective therapeutic option for persistent, recurrent, or metastatic cervical cancer and the potential widespread benefits of antibody drug conjugates like pembrolizumab.

article thumbnail

Evernorth inks strategic partnership with CarepathRx Health System Solutions

Fierce Healthcare

Evernorth has inked a strategic partnership with CarepathRx Health System Solutions that aims to boost access to specialty pharmacy care. | Evernorth has inked a strategic partnership with CarepathRx Health System Solutions that aims to boost access to specialty pharmacy care.

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

With Perioperative Pembrolizumab, Event-Free Survival for Early-Stage Lung Cancer Was 62% at the Interim Analysis of Phase 3 KEYNOTE-671

Pharmacy Times

Expert said these striking results, coupled with benefits across all subgroups and potential overall survival, suggests efficacy for adults with early-stage non-small cell lung cancer.

65
article thumbnail

Soy Sauce Helps Ease the Pain of a Burn

The People's Pharmacy

Sometimes we learn about a surprising home remedy and then we hear from scores or even hundreds of people that they have used it successfully. More than a decade ago, a listener to our radio show called to tell us that soy sauce helps ease the pain and redness of a burn. We have been getting responses from other listeners and from readers ever since then.

61
article thumbnail

Targeting Folate Receptor Alpha is Ideal for Ovarian Cancer Treatment

Pharmacy Times

FR alpha expression is limited on normal cells, but upregulated on cancers such as ovarian, endometrial, and triple-negative breast cancers.

73
article thumbnail

ASCO: AZ gets a practice-changing win in lung cancer

pharmaphorum

ASCO: AZ gets a practice-changing win in lung cancer Phil.

96
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Innovation in immuno-oncology: Leading companies in T-cell culturing

Pharmaceutical Technology

The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: T-cell culturing.

article thumbnail

ASCO: Can Imfinzi bring immunotherapy to ovarian cancer?

pharmaphorum

ASCO: Can Imfinzi bring immunotherapy to ovarian cancer? Phil.

88
article thumbnail

Leading innovators in transcription factors for genetically modified cells for the pharmaceutical industry

Pharmaceutical Technology

The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Transcription factors

article thumbnail

Gilead and Arcus Present P-II Study (ARC-7) Results of Domvanalimab as 1L Treatment of Non-Small Cell Lung Cancer at ASCO 2023

PharmaShots

Shots: The interim analysis from the P-II study evaluating domvanalimab + zimberelimab (doublet) & domvanalimab + zimberelimab and etrumadenant (triplet) vs zimberelimab monotx. in a ratio (1:1:1) in 150 patients with PD-L1 TPS ≥50% and no EGFR or ALK mutations As the time of data cutoff of Feb 2023, improvement in PFS vs zimberelimab monotx. with a median follow-up time of ~18mos., 33% reduction in risk of disease progression or death for doublet & 28% for triplet Zimberelimab monotx

40
article thumbnail

Pharmaceutical Thermal Packaging 4.0: Sonoco ThermoSafe

Pharmaceutical Commerce

undefined

article thumbnail

Leading innovators in transcription factors for AAV for the pharmaceutical industry

Pharmaceutical Technology

The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on on Innovation in Pharmaceuticals: Transcription facto

Hospitals 105
article thumbnail

Connecticut Favorites – Beauty

The Luxe Pharmacist

Hi friends, I get so many questions about where I get my hair, lashes, nails, etc done in Connecticut so I figured I’d do a round up blog post of all my favorites places! This version is all things beauty in CT, but I hope to expand to restaurants, coffee shops and more in the future so let me know in the comments if there’s anything specific you want to see in a future CT round up!

75